Moderna CEO Says Its Cancer Vaccine Isn’t a Disappointment, It’s a Blockbuster

What happened: Moderna's stock fell on Thursday after a data leak concerning its cancer-vaccine candidate, which is co-developed with Merck. Why it matters: The leak preceded the company's public disclosure of the data, and the CEO's response framed the vaccine as a blockbuster rather than a disappointment. Market: -3.2% today ($140.61), +33.1% YTD, 1.3x vol — as of 23:30 UTC Verified: Q3_2026 (Oct 29) revenue $17.3B vs $17.3B est; next print ~Jan 28

Moderna's stock fell on Thursday after a data leak concerning its cancer-vaccine candidate, which is co-developed with Merck.

The leak preceded the company's public disclosure of the data, and the CEO's response framed the vaccine as a blockbuster rather than a disappointment. Market: -3.2% today ($140.61), +33.1% YTD, 1.3x vol — as of 23:30 UTC Verified: Q3_2026 (Oct 29) revenue $17.3B vs $17.3B est; next print ~Jan 28